A Phase 4 interventional study of Intramuscular ephedrine and Placebo in Ephedrine, Intramuscular and Hypotension, sponsored by Hospital de Base. Status unknown at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-12.
Sponsored by Hospital de Base · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing ephedrine in Hypotension — 4 open to participants now, 4 under way, none of them phase 3. Ephedrine · Hypotension.
Among the 22 studies testing ephedrine in Hypotension, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2022, is one of 11 in phase 4, and was the 15th registered.
892 studies on the registry are indexed under Hypotension; 199 are open to participants now.
Browse Hypotension studies →4 of the 22 studies testing ephedrine in Hypotension are open now, in 2 countries. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 50+
Cairo University · Sites in Egypt
Ages 18–40 · Women only
Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Sites in Canada
Ages 19–40 · Women only · Healthy volunteers
Seoul National University Hospital
Ages up to 2
By country, each count listing its studies:
Ephedrine: first FDA approval 2016 (AKOVAZ). What it is approved for, and how studies give it, is on its page →
Of the 114 Hypotension studies recruiting now, 53 (46%) set no upper age limit and 36 (32%) stop at 75 or younger; 7 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 1 · Phase 4 11
First in 2004; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 202 is above the median of 86 across 593 interventional studies indexed under Hypotension.
Median enrollment 120 across the 22 interventional studies. Of the 15 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 22 has an industry lead sponsor. The 10 most frequent:
Hospital de Base is the lead sponsor of 25 studies on the registry; 5 are open to participants now.
Hospital de Base has 2 studies filed under Hypotension — fewer than ten, so there is no comparison to draw.
4 of the studies testing ephedrine in Hypotension that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07379710Cairo UniversityNorepinephrine With Ephedrine Versus Norepinephrine Alone During Spinal Anesthesia for Cesarean Delivery | 2026-12 |
| NCT07722013Cairo UniversityIntermittent Ephedrine Boluses for Prophylaxis Against Postinduction Hypotension | 2026-12 |
| NCT04053478Samuel Lunenfeld Research Institute, Mount Sinai HospitalEffects of Ephedrine, Phenylephrine, Norepinephrine and Vasopressin on Contractility of Human Myometrium and Umbilical Vessels: An In-vitro Study | 2026-12 |
| NCT06257316Seoul National University HospitalAppropriate Dosage of Vasopressor in Neonates and Infants | 2027-02-28 |
Add all 4 to your calendar (.ics) → With an account.
Among the 22 studies testing ephedrine in Hypotension, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Subarachnoid anesthesia is an alternative and usually the first choice for many surgical procedures. It is a simple and safe procedure, however it can present complications such as hypotension and bradycardia. In this sense, ephedrine, an alpha and beta agonist agent, commonly used as rescue therapy for these events, is also potentially useful for prophylaxis of this unwanted effect and for less hemodynamic variation when preventively administered via the intramuscular route. Two groups will be divided: intramuscular ephedrine (0.5 mg/kg) and placebo. The variables analyzed and compared will be the incidence of hypotension and bradycardia, variation in mean and systolic blood pressure, heart rate, in addition to side effects. The main objective is to verify if the use of intramuscular ephedrine prior to spinal block is able to reduce the incidence of hypotension.
Subarachnoid or spinal anesthesia is an alternative and usually the first choice for many surgical procedures of the lower limbs, perineum and lower abdomen. It is a simple and safe procedure, however it can present complications such as hypotension and bradycardia. The incidence of hypotension and bradycardia is approximately 30 and 10%, respectively, during spinal anesthesia, however, the incidence of hypotension can be as high as 50 to 60% in obstetric patients.
In this sense, it is common for ephedrine, an agent with beta and alpha agonist action, to be the medication of first choice for rescuing hypotension and bradycardia after subarachnoid block, with part of its action happening by a direct mechanism and part by stimulus and indirect release. of endogenous catecholamines stored in the adrenal.
It is known that intramuscular administration has slower absorption and lower bioavailability of the drug compared to intravenous administration. Therefore, we have in our favor: a later serum peak, coinciding with the establishment of sympathetic block after spinal anesthesia, as well as more insidious effects, with less tendency to peaks and valleys and greater hemodynamic stability when compared to therapy alone. intravenous rescue. To assess this response, the main objective of the present study is to verify the hypothesis that the previous administration of ephedrine by intramuscular route reduces the incidence of hypotension induced by spinal anesthesia.
The proposal is a prospective, randomized, double-blind, placebo-controlled study in surgical procedures. Examiners responsible for evaluating patients will not have access to the agents used. Patients will be randomized through a list generated by lottery. The examiner responsible for opening the envelope, will perform the drawing, include the patient in one of the groups, write down his/her data in the random list, prepare the syringe with the medication, and deliver it to the operating room so that the following examiners will not be aware of the administered drug.
Patients will receive standard monitoring, venoclysis, intravenous midazolam as pre-anesthetic medication. Then, the study drug will be administered (ephedrine 0.3mg/kg intramuscularly or placebo). All patients received spinal anesthesia with hyperbaric bupivacaine and opioid adjuvants at the discretion of the anesthesiologist, except clonidine.
The evolution of vital signs such as systolic and mean blood pressure, heart rate, height of sensory block, incidence of adverse events such as bradycardia, tachycardia, hypertension or hypotension, nausea, vomiting, consumption of vasopressors and antiemetics will be evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive intramuscular ephedrine 0,5 mg/kg before spinal anesthesia
Drug: Intramuscular ephedrine · Drug: Placebo
Patients will receive intramuscular saline before spinal anesthesia
Drug: Intramuscular ephedrine · Drug: Placebo
Patients will receive prophylactic intramuscular ephedrine plus standard spinal anesthesia
Patients will receive prophylactic intramuscular saline plus standard spinal anesthesia
Number of participants with adverse events as hypotension
Intraoperative hemodynamic stability analysis through the incidence of bradycardia, hypotension and consumed vasopressors
Time frame: During surgery
Started Jul 2022 (actual). Primary completion is estimated for Jul 2023, 12 months after the start.
Of 61 non-industry phase 4 interventional studies under Hypotension, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's planned 12 months is close to that.
Counting every sponsor, half of 62 studies reached it within 12 months; a quarter within 5 and three quarters within 20.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ephedrine
Hospital de Base